Overview of comments received on `Nilotinib hard capsules 50, 150 and 200 mg product-specific bioequivalence guidance’ (EMA/CHMP/518671/2023)

Overview of comments received on `Nilotinib hard capsules 50, 150 and 200 mg product-specific bioequivalence guidance’ (EMA/CHMP/518671/2023)

Human medicines European public assessment report (EPAR): Myalepta, metreleptin, Date of authorisation: 29/07/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Myalepta, metreleptin, Date of authorisation: 29/07/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): CoAprovel, irbesartan,hydrochlorothiazide, Date of authorisation: 14/10/1998, Revision: 52, Status: Authorised

Human medicines European public assessment report (EPAR): CoAprovel, irbesartan,hydrochlorothiazide, Date of authorisation: 14/10/1998, Revision: 52, Status: Authorised

Human medicines European public assessment report (EPAR): Karvezide, irbesartan,hydrochlorothiazide, Date of authorisation: 16/10/1998, Revision: 50, Status: Authorised

Human medicines European public assessment report (EPAR): Karvezide, irbesartan,hydrochlorothiazide, Date of authorisation: 16/10/1998, Revision: 50, Status: Authorised

Human medicines European public assessment report (EPAR): Repaglinide Teva, repaglinide, Date of authorisation: 28/06/2009, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Repaglinide Teva, repaglinide, Date of authorisation: 28/06/2009, Revision: 10, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.